QuidelOrtho Corp. Stock
€21.80
Your prediction
QuidelOrtho Corp. Stock
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
Cons
Performance of QuidelOrtho Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | 0.000% | -9.917% | -10.656% | -31.875% | -48.095% | -78.416% | -90.439% |
Veeva Systems A | 0.290% | 0.831% | -0.164% | 41.327% | 19.488% | 15.950% | 8.635% |
Thermo Fisher Scientific Inc. | 11.540% | 0.930% | 5.254% | -27.584% | -27.185% | -33.891% | 2.509% |
Waters Corp. | 2.290% | -2.043% | -18.771% | -15.835% | -31.243% | -27.791% | 26.031% |
Comments
News

QuidelOrtho to Participate in Upcoming Investor Conferences
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

QuidelOrtho Reports First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and

QuidelOrtho to Report First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and